CliffBio
small molecule

CORLANOR

IVABRADINE

Loss of exclusivityDecember 2026latest FDA-listed patent expiry
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameCORLANOR
Active ingredientIVABRADINE
Strength5MG/5ML (1MG/ML)
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalApril 2019
Marketing statusDISCN

Listed patents

PatentExpiresType
7867996December 2026substance, product
7361650February 2026substance, product
7361649February 2026substance, product
7879842February 2026substance, product

Regulatory exclusivity

CodeExpires
PEDOctober 2026
ODE-234April 2026

More from Amgen

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.